Lomitapide, relief pitcher for patients with homozygous familial hypercholesterolemia

被引：4
|
作者：
Kim, Sang-Hyun [1 ]
Baek, Sang Hong [2 ]
机构：
[1] Seoul Natl Univ, Seoul Boramae Hosp, Coll Med, Cardiol,Internal Med, Seoul, South Korea
[2] Catholic Univ Korea, Seoul St Marys Hosp, Internal Med, Cardiovasc Med, Seoul, South Korea
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2020年 / 27卷 / 02期
关键词：
EFFICACY;
D O I：
10.1177/2047487319881240
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
  • [31] New insights into the management of homozygous familial hypercholesterolemia patients treated with lomitapide: a single-center experience
    Iannuzzo, Gabriella
    Calcaterra, Ilenia Lorenza
    Gentile, Marco
    Stanzione, Claudia
    de Ruberto, Francesca
    di Taranto, Maria Donata
    Cardiero, Giovanna
    Fortunato, Giuliana
    Di Minno, Matteo
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [32] Lomitapide: a novel drug for homozygous familial hypercholesterolemia (vol 9, pg 19, 2014)
    Panno, Maria D.
    Cefalu, Angelo B.
    Averna, Maurizio R.
    CLINICAL LIPIDOLOGY, 2014, 9 (02) : 278 - 278
  • [33] Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience
    Sperlongano, Simona
    Gragnano, Felice
    Natale, Francesco
    D'Erasmo, Laura
    Concilio, Claudia
    Cesaro, Arturo
    Golia, Enrica
    Crisci, Mario
    Sperlongano, Rossella
    Fimiani, Fabio
    Russo, Mariagiovanna
    Arca, Marcello
    Limongelli, Giuseppe
    Calabro, Paolo
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2018, 19 (03) : 83 - 90
  • [34] A phase 3 study of the microsomal triglyceride transfer protein (MTP) inhibitor lomitapide in patients with homozygous familial hypercholesterolemia
    Cuchel, M.
    EUROPEAN HEART JOURNAL, 2012, 33 : 951 - 951
  • [35] Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia
    Cuchel, Marina
    Blom, Dirk J.
    Averna, Maurizio R.
    ATHEROSCLEROSIS SUPPLEMENTS, 2014, 15 (02) : 33 - 45
  • [36] Management of Patients With Homozygous Familial Hypercholesterolemia
    Ziajka, Paul E.
    AMERICAN JOURNAL OF MANAGED CARE, 2013, 19 (13): : S251 - S258
  • [37] Managing Patients With Homozygous Familial Hypercholesterolemia
    Gidding, Samuel S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (09) : 1171 - 1172
  • [38] Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
    Blom, Dirk J.
    Averna, Maurizio R.
    Meagher, Emma A.
    Theron, Hendrik du Toit
    Sirtori, Cesare R.
    Hegele, Robert A.
    Shah, Prediman K.
    Gaudet, Daniel
    Stefanutti, Claudia
    Vigna, Giovanni B.
    Larrey, Dominique
    Bloedon, LeAnne T.
    Foulds, Pamela
    Rader, Daniel J.
    Cuchel, Marina
    CIRCULATION, 2017, 136 (03) : 332 - 335
  • [39] Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia
    Won, Jane I.
    Zhang, Jun
    Tecson, Kristen M.
    McCullough, Peter A.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2017, 18 (01) : 21 - 28
  • [40] Long-termliver safety of lomitapide in patients with homozygous familial hypercholesterolemia: Three-year data from the lomitapide observational worldwide evaluation registry (LOWER)
    Larrey, D.
    Underberg, J.
    Cannon, C.
    Makris, L.
    Jurecka, A.
    Blom, D.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S588 - S588
12345